140 related articles for article (PubMed ID: 19287100)
1. Pancreatic cancer: translating lessons from mouse models.
Strimpakos AS; Hoimes C; Saif MW
JOP; 2009 Mar; 10(2):98-103. PubMed ID: 19287100
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics in pancreatic cancer.
Tourkantonis IS; Peponi E; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):335-9. PubMed ID: 25076337
[TBL] [Abstract][Full Text] [Related]
3. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2009 Jul; 10(4):357-60. PubMed ID: 19581734
[TBL] [Abstract][Full Text] [Related]
6. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
7. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?
Kleespies A; Jauch KW; Bruns CJ
Drug Resist Updat; 2006; 9(1-2):1-18. PubMed ID: 16621676
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Oberstein PE; Saif MW
JOP; 2011 Mar; 12(2):96-100. PubMed ID: 21386629
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
de Sousa Cavalcante L; Monteiro G
Eur J Pharmacol; 2014 Oct; 741():8-16. PubMed ID: 25084222
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
14. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
15. Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2010 Mar; 11(2):124-7. PubMed ID: 20208318
[TBL] [Abstract][Full Text] [Related]
16. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Mercier C; Evrard A; Ciccolini J
J Clin Oncol; 2007 Oct; 25(30):4855; author reply 4855-6. PubMed ID: 17947739
[No Abstract] [Full Text] [Related]
17. What options are available for refractory pancreatic cancer?
Choi M; Kim R; Saif MW
JOP; 2012 Mar; 13(2):163-5. PubMed ID: 22406591
[TBL] [Abstract][Full Text] [Related]
18. Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Richter J; Saif MW
JOP; 2010 Mar; 11(2):144-7. PubMed ID: 20208323
[TBL] [Abstract][Full Text] [Related]
19. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Maréchal R; Van Laethem JL
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]